1. Home
  2. PAI vs CGEN Comparison

PAI vs CGEN Comparison

Compare PAI & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PAI
  • CGEN
  • Stock Information
  • Founded
  • PAI 1973
  • CGEN 1993
  • Country
  • PAI United States
  • CGEN Israel
  • Employees
  • PAI N/A
  • CGEN N/A
  • Industry
  • PAI Trusts Except Educational Religious and Charitable
  • CGEN Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • PAI Finance
  • CGEN Health Care
  • Exchange
  • PAI Nasdaq
  • CGEN Nasdaq
  • Market Cap
  • PAI 121.8M
  • CGEN 126.2M
  • IPO Year
  • PAI N/A
  • CGEN 2000
  • Fundamental
  • Price
  • PAI $12.41
  • CGEN $1.45
  • Analyst Decision
  • PAI
  • CGEN Strong Buy
  • Analyst Count
  • PAI 0
  • CGEN 2
  • Target Price
  • PAI N/A
  • CGEN $4.00
  • AVG Volume (30 Days)
  • PAI 25.0K
  • CGEN 287.5K
  • Earning Date
  • PAI 01-01-0001
  • CGEN 11-12-2024
  • Dividend Yield
  • PAI 4.78%
  • CGEN N/A
  • EPS Growth
  • PAI N/A
  • CGEN N/A
  • EPS
  • PAI N/A
  • CGEN 0.02
  • Revenue
  • PAI N/A
  • CGEN $59,852,000.00
  • Revenue This Year
  • PAI N/A
  • CGEN $18.69
  • Revenue Next Year
  • PAI N/A
  • CGEN N/A
  • P/E Ratio
  • PAI N/A
  • CGEN $79.82
  • Revenue Growth
  • PAI N/A
  • CGEN 698.03
  • 52 Week Low
  • PAI $10.59
  • CGEN $0.62
  • 52 Week High
  • PAI $12.63
  • CGEN $3.03
  • Technical
  • Relative Strength Index (RSI)
  • PAI 39.69
  • CGEN 35.64
  • Support Level
  • PAI $12.62
  • CGEN $1.35
  • Resistance Level
  • PAI $12.94
  • CGEN $1.85
  • Average True Range (ATR)
  • PAI 0.26
  • CGEN 0.10
  • MACD
  • PAI -0.03
  • CGEN -0.02
  • Stochastic Oscillator
  • PAI 3.67
  • CGEN 20.00

About PAI Western Asset Investment Grade Income Fund Inc.

Western Asset Investment Grade Income Fund Inc is a closed-end diversified investment company. The company designed primarily as a long-term investment and not as a trading vehicle. The fund seeks a high level of current income, consistent with prudent investment risk, through investment in a diversified portfolio of debt securities. Its portfolio is invested in securities which may be convertible into or exchangeable for, or carry warrants to purchase, common stock or other equity interests; and preferred stock.

About CGEN Compugen Ltd.

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902, bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.

Share on Social Networks: